Heart Failure and Cardiogenic Shock in COVID-19
Abstract
Coronavirus disease 2019 (COVID-19) emerged in Wuhan, China, in 2019. It was declared a pandemic in 2020 due to the high number of infected patients, its elevated transmissibility, and unfavorable outcomes. COVID-19 primarily causes pulmonary disease —which can become severe— with varying degrees of systemic involvement. It is frequently associated with cardiovascular complications such as heart failure, cardiogenic shock, and increased cardiovascular and overall mortality. The aim of this review article is to describe key aspects of the diagnosis and treatment of heart failure and cardiogenic shock in patients with COVID-19, as both clinical conditions can be part of the disease's presentation and are among its most common complications in critically ill patientes. Other associated conditions may include myocarditis, acute ischemic events, and arrhythmias. Their presence in patients with this viral infection correlates with a worse prognosis and higher mortality.Downloads
References
1. Phelan AL, Katz R, Gostin LO. The Novel Coronavirus Originating in Wuhan, China: Challenges for Global Health Governance. JAMA. 2020;323(8):709-10. DOI: https://doi.org/10.1001/jama.2020.1097
2. Feng Y, Ling Y, Bai T, Xie Y, Huang J, Li J, et al. COVID-19 with Different Severities: A Multicenter Study of Clinical Features. Am J Respir Crit Care Med. 2020;201(11):1380-8. DOI: https://doi.org/10.1164/rccm.202002-0445oc
3. Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. JAMA. 2020;323(18):1775-6. DOI: https://doi.org/10.1001/jama.2020.4683
4. López-Ponce de León JD, Cárdenas-Marín PA, Giraldo-González GC, Herrera-Escandón A. Coronavirus -- COVID 19: Más allá de la enfermedad pulmonar, qué es y qué sabemos del vínculo con el sistema cardiovascular. Rev Colomb Cardiol. 2020;27(3):142-52. DOI: https://doi.org/10.1016/j.rccar.2020.04.006
5. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382(18):1708-20. DOI: https://doi.org/10.1056/nejmoa2002032
6. Yang C, Jin Z. An Acute Respiratory Infection Runs Into the Most Common Noncommunicable Epidemic-COVID-19 and Cardiovascular Diseases. JAMA Cardiol. 2020;5(7):743-4. DOI: https://doi.org/10.1001/jamacardio.2020.0934
7. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-726. DOI: https://doi.org/10.1093/eurheartj/ehab368
8. Mesa González M, Correa Padilla JM, Abreu Cruz AA. Complicaciones cardiovasculares en COVID-19. Boletín Científico del CIMEQ [Internet]. 2020 [citado 11 Feb 2022];1(16):5-6. Disponible en: https://instituciones.sld.cu/bolcimeq/2020/07/06/429/
9. Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ [Internet]. 2020 [citado 11 Feb 2022];368:m1091. Disponible en: https://doi.org/10.1136/bmj.m1091
10. Szekely Y, Lichter Y, Taieb P, Banai A, Hochstadt A, Merdler I, et al. Spectrum of Cardiac Manifestations in COVID-19: A Systematic Echocardiographic Study. Circulation. 2020;142(4):342-53. DOI: https://doi.org/10.1161/circulationaha.120.047971
11. Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - An update on the status. Mil Med Res [Internet]. 2020 [citado 15 Feb 2022];7(1):11. Disponible en: https://doi.org/10.1186/s40779-020-00240-0
12. Ochoa Montes LA. Complicaciones y mortalidad cardiovascular durante la COVID-19. Grupo de Investigación en Muerte Súbita (GIMUS). Acta Méd [Internet]. 2020 [citado 15 Feb 2022];21(4):e155. Disponible en: https://revactamedica.sld.cu/index.php/act/article/view/155/pdf
13. Lippi G, Sanchis-Gomar F, Henry BM. Coronavirus disease 2019 (COVID-19): The portrait of a perfect storm. Ann Transl Med. 2020;8(7):497. DOI: https://doi.org/10.21037/atm.2020.03.157
14. Hu H, Ma F, Wei X, Fang Y. Coronavirus fulminant myocarditis treated with glucocorticoid and human immunoglobulin. Eur Heart J. 2021;42(2):206. DOI: https://doi.org/10.1093/eurheartj/ehaa190
15. Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020;17(5):259-60. DOI: https://doi.org/10.1038/s41569-020-0360-5
16. Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiol. 2020;5(7):802-10. DOI: https://doi.org/10.1001/jamacardio.2020.0950
17. Wong CK, Lam CW, Wu AK, Ip WK, Lee NL, Chan IH, et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol. 2004;136(1):95-103. DOI: https://doi.org/10.1111/j.1365-2249.2004.02415.x
18. Giudicessi JR, Noseworthy PA, Friedman PA, Ackerman MJ. Urgent Guidance for Navigating and Circumventing the QTc-Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for Coronavirus Disease 19 (COVID-19). Mayo Clin Proc. 2020;95(6):1213-21. DOI: https://doi.org/10.1016/j.mayocp.2020.03.024
19. Chen D, Li X, Song Q, Hu C, Su F, Dai J, et al. Assessment of Hypokalemia and Clinical Characteristics in Patients With Coronavirus Disease 2019 in Wenzhou, China. JAMA Netw Open [Internet]. 2020 [citado 16 Feb 2022];3(6):e2011122. Disponible en: https://doi.org/10.1001/jamanetworkopen.2020.11122
20. Liu K, Fang YY, Deng Y, Liu W, Wang MF, Ma JP, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J (Engl). 2020;133(9):1025-31. DOI: https://doi.org/10.1097/cm9.0000000000000744
21. De Juan Bagudá J, Farrero Torres M, García-Cosío MD, Recio Mayoral A, Sabé Fernández N, García Pinilla JM. Implicaciones de la pandemia por COVID-19 para el paciente con insuficiencia cardiaca, trasplante cardiaco y asistencia ventricular. Recomendaciones de la Asociación de Insuficiencia Cardiaca de la Sociedad Española de Cardiología. REC: CardioClinics. 2020;55(2):94-102. DOI: https://doi.org/10.1016/j.rccl.2020.03.007
22. Prieto-Alhambra D, Balló E, Coma E, Mora N, Aragón M, Prats-Uribe A, et al. Filling the gaps in the characterization of the clinical management of COVID-19: 30-day hospital admission and fatality rates in a cohort of 118 150 cases diagnosed in outpatient settings in Spain. Int J Epidemiol. 2021;49(6):1930-9. DOI: https://doi.org/10.1093/ije/dyaa190
23. Wu Q, Zhou L, Sun X, Yan Z, Hu C, Wu J, et al. Altered Lipid Metabolism in Recovered SARS Patients Twelve Years after Infection. Sci Rep. 2017;7(1):9110. DOI: https://doi.org/10.1038/s41598-017-09536-z
24. Soria Arcos F, Romero Puche A, Vicente Vera T. Controversias sobre el tratamiento con IECA/ARA-II y COVID-19. Rev Esp Cardiol. 2020;73(6):516. DOI: https://doi.org/10.1016/j.recesp.2020.03.014
25. Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005;436(7047):112-6. DOI: https://doi.org/10.1038/nature03712
26. Nicholls J, Peiris M. Good ACE, bad ACE do battle in lung injury, SARS. Nat Med. 2005;11(8):821-2. DOI: https://doi.org/10.1038/nm0805-821
27. Xu X, Chen P, Wang J, Feng J, Zhou H, Li X, et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China Life Sci. 2020;63(3):457-60. DOI: https://doi.org/10.1007/s11427-020-1637-5
28. Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020;46(4):586-90. DOI: https://doi.org/10.1007/s00134-020-05985-9
29. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines [Internet]. Bethesda (MD): National Institutes of Health (US); 2021. Enlace: https://www.ncbi.nlm.nih.gov/books/NBK570371/pdf/Bookshelf_NBK570371.pdf
30. Sánchez-Recalde Á, Solano-López J, Miguelena-Hycka J, Martín-Pinacho JJ, Sanmartín M, Zamorano JL. COVID-19 y shock cardiogénico: diferentes formas de presentación cardiovascular con alta mortalidad. Rev Esp Cardiol. 2020;73(8):669-72. DOI: https://doi.org/10.1016/j.recesp.2020.04.018
31. Álvarez-Rosales H, Fernández-Rivera BJ, Guillén-Rojas R, Escamilla-Ríos DE, Herrera-Elizalde R, Telona-Fermán E, et al. Recomendaciones para el manejo de la vía aérea en caso sospechoso y/o confirmado con COVID-19. Protocolo del Departamento de Anestesiología Cardiovascular del Instituto Nacional de Cardiología Ignacio Chávez. Arch Cardiol Mex. 2021;91(Supl. COVID):095-101. DOI: https://doi.org/10.24875/acm.20000377
32. Melhaoui I, Oujidi Y, El Heddad IA, Bensaid A, Bkiyar H, Bentata Y, et al. Management of post cardiac transplantation immunosuppression and COVID-19: A case report. Ann Med Surg (Lond) [Internet]. 2021 [citado 21 Feb 2022];71:102875. Disponible en: https://doi.org/10.1016/j.amsu.2021.102875
33. Lima B, Gibson GT, Vullaganti S, Malhame K, Maybaum S, Hussain ST, et al. COVID-19 in recent heart transplant recipients: Clinicopathologic features and early outcomes. Transpl Infect Dis [Internet]. 2020 [citado 22 Feb 2022];22(5):e13382. Disponible en: https://doi.org/10.1111/tid.13382
Downloads
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
